肿瘤相关自身抗体的产生机制及临床研究与应用  

Production mechanism,clinical research and application of tumor related autoantibodies

作　　者：周海舟[1] 关秀茹[1] Zhou Haizhou;Guan Xiuru(Department of Laboratory Diagnosis,the First Affiliated Hospital of Harbin Medcal University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院检验科,哈尔滨150001

出　　处：《中华检验医学杂志》2023年第11期1123-1127,共5页Chinese Journal of Laboratory Medicine

摘　　要：肿瘤相关自身抗体(TAAS)作为癌症生物标志物已引起人们的特别关注。近年来研究发现,其在癌症的早期阶段表现出升高的水平,并且在多种癌症中具有很好的预测价值。本文介绍了TAAS产生的机制及其临床应用,并对肿瘤自身抗体作为生物学标记的优势及面临的问题进行了阐述。Tumor-associated autoantibodies(TAAS),as cancer biomarkers,have attracted special attention.In recent years,increasing evidence has indicated that TAAS shows an elevated level in the early stage of human malignancies,and examination of TAAS in patients′clinical specimens has a good predictive value for a variety of cancers′early diagnosis.The mechanism of TAAS and its clinical application will be introduced,and the advantages and problems of tumor autoantibodies as markers will be expounded in this article.

关 键 词：肿瘤相关 自身抗体 抗原 生物学标记 

分 类 号：R730.3[医药卫生—肿瘤]